Literature DB >> 18334063

Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis.

Y P Bao1, N Li, J S Smith, Y L Qiao.   

Abstract

The aim of the study was to determine human papillomavirus (HPV) type-distribution in the cervix of Chinese women, and to estimate the potential future impact of HPV prophylactic vaccines for cervical cancer prevention in China. A total of 32 studies using polymerase chain reaction for HPV detection were included in the meta-analysis, including 2844 invasive cervical cancer (ICC), 820 high-grade squamous intraepithelial lesions (HSIL), 432 low-grade squamous intraepithelial lesions (LSIL) and 2902 women with normal cytology/histology. The overall and type-specific HPV prevalence of 18 HPV types (HPV 6, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73 and 82 of different cervical stages) were estimated. Overall HPV prevalence was 83.7%, 66.2%, 61.3% and 11.2% in ICC, HSIL, LSIL and normal, respectively. HPV 16 was the predominant type in all cervical stages. Estimated HPV 16/18 positive fractions in ICC, HSIL, LSIL and normal were 69.7%, 45.5%, 32.23% and 4.6%, respectively. HPV-16/18 vaccine has the 69.7% potential prevention in ICC. HPV 58 and 52 were the priority HPV types in Chinese women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334063     DOI: 10.1258/ijsa.2007.007113

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  20 in total

1.  Evaluation of high-risk human papillomaviruses type distribution in cervical cancer in Sichuan province of China.

Authors:  En-qi Wu; Guo-nan Zhang; Xiang-hui Yu; Yuan Ren; Ying Fan; Yong-ge Wu; Wei Kong; Xiao Zha
Journal:  BMC Cancer       Date:  2008-07-22       Impact factor: 4.430

2.  Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.

Authors:  Jia Ji; Hai-Kui Sun; Jennifer S Smith; He Wang; Mark T Esser; Shangying Hu; Robert G Pretorius; Wen Chen; Jerome L Belinson; You-Lin Qiao
Journal:  BMC Infect Dis       Date:  2012-06-20       Impact factor: 3.090

3.  Genital HPV infection among heterosexual and homosexual male attendees of sexually transmitted diseases clinic in Beijing, China.

Authors:  H N Xin; H J Li; Z Li; X W Li; M F Li; H R Zhang; B X Feng; W H Lun; H W Yan; J Long; L Gao
Journal:  Epidemiol Infect       Date:  2017-08-08       Impact factor: 4.434

4.  Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study.

Authors:  Stephanie Si Liu; Kelvin Yuen Kwong Chan; Rebecca Ching Yu Leung; Karen Kar Loen Chan; Kar Fai Tam; May Hiu Mei Luk; Sue Seen Tsing Lo; Daniel Yee Tak Fong; Annie Nga Yin Cheung; Zhong Qiu Lin; Hextan Yuen Sheung Ngan
Journal:  PLoS One       Date:  2011-05-03       Impact factor: 3.240

5.  Comparison of prevalence, viral load, physical status and expression of human papillomavirus-16, -18 and -58 in esophageal and cervical cancer: a case-control study.

Authors:  Donghong Zhang; Qingying Zhang; Li Zhou; Leijun Huo; Yi Zhang; Zhongying Shen; Yi Zhu
Journal:  BMC Cancer       Date:  2010-11-26       Impact factor: 4.430

6.  Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.

Authors:  Fengcai Zhu; Juan Li; Yuemei Hu; Xiang Zhang; Xiaoping Yang; Hui Zhao; Junzhi Wang; Jianguo Yang; Guodong Xia; Qinyong Dai; Haiwen Tang; Pemmaraju Suryakiran; Sanjoy K Datta; Dominique Descamps; Dan Bi; Frank Struyf
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Human papillomavirus infection in Beijing, People's Republic of China: a population-based study.

Authors:  R Zhao; W Y Zhang; M H Wu; S W Zhang; J Pan; L Zhu; Y P Zhang; H Li; Y S Gu; X Z Liu
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

8.  Genotype-specific Distribution and Change of High-risk Human Papillomavirus Infection and the Association with Cervical Progression Risk in Women with Normal Pathology and Abnormal Cytology in a Population-based Cohort Study in China.

Authors:  Haixia Jia; Ling Ding; Yang Han; Yuanjing Lyu; Min Hao; Zhiqiang Tian; Jintao Wang
Journal:  J Cancer       Date:  2021-05-19       Impact factor: 4.207

9.  Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.

Authors:  Feng-Cai Zhu; Wen Chen; Yue-Mei Hu; Ying Hong; Juan Li; Xun Zhang; Yi-Ju Zhang; Qin-Jing Pan; Fang-Hui Zhao; Jia-Xi Yu; Yan-Shu Zhang; Xiaoping Yang; Cheng-Fu Zhang; Haiwen Tang; Helen Zhang; Marie Lebacq; Marie-Pierre David; Sanjoy K Datta; Frank Struyf; Dan Bi; Dominique Descamps
Journal:  Int J Cancer       Date:  2014-05-20       Impact factor: 7.396

10.  Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.

Authors:  Fang-Hui Zhao; Feng-Cai Zhu; Wen Chen; Juan Li; Yue-Mei Hu; Ying Hong; Yi-Ju Zhang; Qin-Jing Pan; Jia-Hong Zhu; Xun Zhang; Yong Chen; Haiwen Tang; Helen Zhang; Christelle Durand; Sanjoy K Datta; Frank Struyf; Dan Bi
Journal:  Int J Cancer       Date:  2014-05-20       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.